Abivax SA Sponsored ADR (ABVX) AI Stock Analysis

• Market Cap: $450.95M
• Dividend Yield: N/A
• Average Volume (3M): 137.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: N/A
• EPS Growth: -4.53%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.79
• Shares Outstanding: 63,418,750
• 10 Day Avg. Volume: 95,930
• 30 Day Avg. Volume: 137,071
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $35.00
• Price Target Upside: 418.52% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

Abivax SA has strong revenue growth but faces challenges with profitability, heavily relying on external financing. The technical indicators show a bearish trend, and the valuation remains unattractive due to negative earnings. The lack of substantial guidance or sentiment from the earnings call provides limited insight into future performance. Overall, the stock is positioned in a challenging environment typical of biotech firms in growth stages.

Positive Factors

Clinical Trials

The Data Safety Monitoring Board has not observed any new safety signals, indicating a positive safety profile for the trials.

Market Potential

Topline 8-week induction data are expected to have the potential to be one of the biggest biotech stock moves given the low valuation of ABVX currently versus historical IBD comparisons.

Negative Factors

Financial Performance

The net loss per share in 2024 was €176.2M, or (€2.80/share).

Financial Status

Years of cash left is less than 1.0, indicating potential financial strain.

Abivax SA Sponsored ADR Business Overview & Revenue Model

Company Description

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

How the Company Makes Money

Abivax SA primarily generates revenue through the development and commercialization of its drug candidates. The company invests heavily in research and development to advance its pipeline of therapies through clinical trials. Revenue is expected to be derived from the successful commercialization of these drugs, which may include sales, licensing agreements, and partnerships with larger pharmaceutical companies. Licensing deals and strategic partnerships can provide upfront payments, milestone payments, and royalties based on future sales of the developed therapies. The company may also engage in collaborations with other biotech firms or academic institutions to co-develop and market their treatments, thus sharing both the costs and the potential revenue generated from successful products.

Abivax SA Sponsored ADR Financial Statement Overview

Summary

Abivax SA shows strong revenue growth but struggles with profitability due to consistent net losses and negative margins. The balance sheet is bolstered by a strong cash position, reducing solvency risk, but reliance on external financing is a concern. Overall, the company is on a growth trajectory but faces significant challenges in achieving profitability.

Income Statement

The company shows a trend of increasing revenue over the years, with a significant jump in 2023. However, the net profit margin is negative due to substantial net losses, indicating profitability challenges. Gross profit margin is relatively high, showing operational efficiency, but EBIT and EBITDA margins are deeply negative, suggesting high operating expenses or other costs impacting profitability.

Balance Sheet

The balance sheet highlights a strong cash position, with cash and equivalents significantly exceeding total debt, indicating good liquidity. The debt-to-equity ratio is moderate, suggesting manageable leverage, while return on equity is negative due to net losses. The equity ratio indicates a decent proportion of assets funded by equity.

Cash Flow

Operating cash flow is negative, reflecting challenges in generating cash from core operations. The company has a robust cash inflow from financing activities, suggesting reliance on external funding. Free cash flow is also negative, indicating cash outflows exceed inflows, but there is a positive trend in cash flow improvement.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
4.62M	4.58M	37.00K	63.00K	23.00K
	Gross Profit
3.91M	4.47M	-119.00K	62.00K	7.00K
	EBIT
-127.38M	-56.65M	-42.56M	-38.01M	-33.30M
	EBITDA
-133.21M	-53.31M	-52.03M	-38.00M	-33.22M
	Net Income Common Stockholders
-147.74M	-69.85M	-41.36M	-37.55M	-30.63M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
260.99M	26.95M	60.70M	29.30M	9.77M
	Total Assets
327.06M	73.35M	110.36M	71.30M	51.73M
	Total Debt
55.46M	46.07M	53.45M	33.99M	20.74M
	Net Debt
-196.48M	19.12M	-7.24M	4.70M	10.98M
	Total Liabilities
131.05M	64.65M	74.75M	53.40M	33.14M
	Stockholders Equity
196.01M	8.70M	35.61M	17.90M	18.59M
Cash Flow		Free Cash Flow
-100.28M	-28.03M	-47.30M	-30.72M	-28.41M
	Operating Cash Flow
-100.01M	-27.99M	-45.66M	-29.82M	-27.47M
	Investing Cash Flow
-10.49M	-513.00K	-1.46M	-575.00K	-370.00K
	Financing Cash Flow
340.57M	48.03M	78.51M	49.93M	24.61M

Abivax SA Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.75
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVX, the sentiment is Neutral. The current price of 6.75 is above the 20-day moving average (MA) of 6.50, above the 50-day MA of 6.67, and below the 200-day MA of 8.74, indicating a neutral trend. The MACD of 0.18 indicates Negative momentum. The RSI at 51.61 is Neutral, neither overbought nor oversold. The STOCH value of 32.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ABVX.

Abivax SA Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.23B	3.70	-41.86%	2.84%	16.58%	-0.16%
ABVX	46 Neutral	$450.95M	―	-147.48%	―	―	-4.53%
CELC	44 Neutral	$382.93M	―	-87.54%	―	―	-4.14%
ALMS	43 Neutral	$236.67M	―	-198.66%	―	―	-82.41%
ORIC	43 Neutral	$403.05M	―	-48.45%	―	―	7.15%
AUTL	42 Neutral	$314.02M	―	-81.91%	―	496.00%	27.50%
ERAS	34 Underperform	$354.08M	―	-43.68%	―	―	10.38%